21-29038357-T-C
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_006447.3(USP16):c.659T>C(p.Leu220Pro) variant causes a missense change. The variant allele was found at a frequency of 0.000000685 in 1,460,256 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_006447.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USP16 | ENST00000399976.7 | c.659T>C | p.Leu220Pro | missense_variant | Exon 7 of 18 | 1 | NM_006447.3 | ENSP00000382858.2 | ||
USP16 | ENST00000399975.7 | c.656T>C | p.Leu219Pro | missense_variant | Exon 7 of 18 | 1 | ENSP00000382857.3 | |||
USP16 | ENST00000474835.5 | n.827T>C | non_coding_transcript_exon_variant | Exon 7 of 17 | 1 | |||||
USP16 | ENST00000334352.8 | c.659T>C | p.Leu220Pro | missense_variant | Exon 8 of 19 | 5 | ENSP00000334808.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460256Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 726512
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:1
The c.659T>C (p.L220P) alteration is located in exon 8 (coding exon 6) of the USP16 gene. This alteration results from a T to C substitution at nucleotide position 659, causing the leucine (L) at amino acid position 220 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.